Investors Contact:Ed BellT: 206.282.7100 E: email@example.com www.CellTherapeutics.com/investors Medical Information Contact: T: 800.715.0944E: firstname.lastname@example.org SOURCE Cell Therapeutics, Inc.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC
Stocks with insider trader activity include SPTN, FL and CTIC
Stocks with insider trader activity include ATRS, CMT and CTIC